Phenotypic and Molecular Detection of Antiseptic Resistance Genes among Clinical Staphylococcus aureus Isolates During COVID-19 Pandemic

Hala Badawi1, Alaa Reda2, Manal El Said1,3, Amira El-Far4, Reham Magdy1, Ahmed El-Shenawy4 and Noha Yousry4

1Department of Microbiology & Infection Prevention & Control Unit, Theodor Bilharz Research Institute (TBI), Giza 12411, Egypt.
2Department of Microbiology & Immunology, Faculty of Medicine, Cairo University, Egypt.
3Department of Microbiology, Medicine Program, Batterjee Medical College, Jeddah 21442, Saudi Arabia.
4Department of Microbiology, Theodor Bilharz Research Institute, (TBI), Egypt.

Abstract

The coronavirus disease (COVID-19) pandemic has expanded the use of chlorhexidine digluconate, a biocide frequently used in hospitals, to inhibit the spread of infection. Genes responsible for resistance against the quaternary ammonium compound qac in Staphylococcus aureus isolates have been shown to confer tolerance to a number of biocidal chemicals, including chlorhexidine. The aim of this study was to determine the occurrence of antiseptic resistance genes (qacA/B and qacC) in clinical isolates of methicillin-susceptible (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). The study also aimed to investigate the association between the presence of the mecA, qacA/B, and qacC genes in MRSA isolates and the susceptibility of the isolates to chlorhexidine to evaluate its future use in the Theodor Bilharz Research Institute (TBI) hospital, following the Centers for Disease Control and Prevention recommendations for patients with MRSA. S. aureus isolates (n = 100) were collected from inpatients and outpatients at TBI. A minimal inhibitory concentration of chlorhexidine was also detected. Polymerase chain reaction was used to detect the mecA, qacA/B, and qacC genes. The results revealed that 84% of S. aureus isolates were MRSA. MRSA (61.9%) and MSSA (68.8%) isolates were susceptible to chlorhexidine. The qacA/B gene was more dominant, being detected in 34%, while qacC was detected in only 5% of S. aureus isolates. All S. aureus isolates with reduced susceptibility to chlorhexidine harbored either the qacA/B or qacC genes. The clinical use of chlorhexidine may continue to increase, emphasizing the significance of continuous caution underlining the emergence of new clones with reduced susceptibility and avoiding antiseptic misuse.

Keywords: Staphylococcus aureus, MRSA, MSSA, Chlorhexidine, qacA/B, qacC Genes, Antiseptic Resistance

*Correspondence: manalmicrobiology@gmail.com
INTRODUCTION

Methicillin-resistant *Staphylococcus aureus* (MRSA) is a nosocomial infection-causing bacterium that can spread extensively among hospital patients and healthcare providers. Infection control strategies used to prevent MRSA infections in hospitals include hand hygiene, along with disinfection of contaminated areas, instruments, and colonized patients. Many antiseptics are used to control MRSA, although abuse and sublethal doses of antiseptics have resulted in the occurrence of MRSA that is less susceptible to antiseptics. An overall increase in the use of antiseptics that occurred after the coronavirus disease 2019 (COVID-19) pandemic has aggravated this problem of the decreased susceptibility of MRSA to antiseptics.

Chlorhexidine is a cationic biguanide that is used as the main antiseptic for infection control in hospitals. This compound is used to decolonize surfaces, bathe patients in the intensive care unit, piercing sites of central venous catheters, preoperative preparation, and hand asepsis. Chlorhexidine kills bacteria by damaging the cytoplasmic membrane and outer cell layers, allowing intracellular contents to escape.

Clinical isolates of *Staphylococcus* with mechanisms resistant to chlorhexidine have been reported. The *qac* genes encode for these mechanisms, which are responsible for resistance to organic cations via proton motive force-dependent multidrug efflux. In staphylococci, six plasmid-encoded *qac* efflux pumps have been identified that belong to two main protein families: the small multidrug resistance family encoded by *qacC*, *qacG*, *qacH*, and *qacJ*, and the major facilitator superfamily, including *qacA* and *qacB* genes.

Resistance to monovalent and divalent organic cations is determined by *qacA*, whereas resistance to monovalent organic cations is governed by a closely related *qacB* determinants. The *qacB* is virtually identical to *qacA*, except for seven to nine bases that are difficult to distinguish using simple Polymerase chain reaction (PCR). *qacC* confers resistance to chlorhexidine and codes for a much smaller membrane protein than the *qacA/B* gene family. MRSA transmission in the intensive care unit can be prevented with a chlorhexidine-based surface antiseptic program; however, strains bearing *qacA/B* genes may be unaffected or spread more promptly.

This study aimed to detect the presence of resistance genes (*qacA/B* and *qacC*) in patients with methicillin-susceptible *S. aureus* (MSSA) and MRSA clinical isolates. We also studied the correlation between existence of *mecA* gene and different antiseptic resistance genes (*qacA/B* and *qacC*) in MRSA isolates and determined the association between the occurrence of *qacA/B* and *qacC* genes and susceptibility to chlorhexidine to evaluate its future use at Theodor Bilharz Research Institute (TBRI) hospital to follow Centers for Disease Control and Prevention (CDC) recommendations for hand hygiene and body wash for patients with MRSA.

MATERIALS AND METHODS

Clinical Isolates

This study was conducted with 100 clinical *S. aureus* isolates obtained from various clinical samples. Specimens were processed at the microbiology laboratory of TBRI between January 2017 and November 2020. *S. aureus* isolates were isolated from 48 urine (48%), 28 (28%) from blood, 16 (16%) from pus, and 8 (8%) from sputum specimens. All specimens included in the study were archived and codes were used, instead of the patient names. The patients’ informed consent was waived as all patient data were anonymized. The study protocol was reviewed and approved by the TBRI institutional review board under Federal Wide Assurance (FWA00010609) and the work was carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for Experiments in Humans and its later amendments (GCP guidelines) or comparable ethical standards. The total number of specimens received at the microbiology lab during this period was 5172; No organisms were detected in 1188 specimens. Out of remaining 3984 specimens, Gram negative was detected in 2880 & Gram positive in 1104, among them, 900 were staphylococci, 100 *S. aureus* and 800 Methicillin-resistant coagulase negative Staphylococci (MRConS). *S. aureus* was identified using traditional methods, at the species level (morphology of the colony, gram staining,
and coagulase and catalase tests). Mannitol fermentation was examined using mannitol salt agar (Bio-Rad). Confirmation of the identified S. aureus isolates was carried out using the Vitek 2 compact automated system that uses fluorogenic methodology for organism identification and a turbidimetric method for susceptibility testing using a 64-well card that provides results in 5–8 h (BioMerieux, France). Of the 100 S. aureus isolates, 84 were MRSA and 16 were MSSA. All S. aureus isolates were kept in glycerol broth at −70°C and then subcultured onto blood agar for 48 h, prior to further investigations, where only 84 and 16 isolates of MRSA and MSSA, respectively, could be elicited with a total of 100 isolates. The MRSA ATCC 43300 standard strain was used as the control.

Detection of mecA-mediated Oxacillin Resistance

Disc diffusion tests were carried out on Mueller–Hinton agar (MAST Diagnostics, UK), and cefoxitin (30 μg) disc were applied. After 16–18 h of incubation at 33–35°C, the zone of inhibition was measured. Clinical Laboratory Standards Institute (CLSI) criteria were used to make the interpretations: mecA-positive was ≤ 21 mm and mecA-negative was ≥ 22 mm. S. aureus isolates that were mecA-positive were reported to be oxacillin-resistant.

Susceptibility of MRSA Strains to Antimicrobial Agents

Antimicrobial susceptibility testing (AST) for different antibiotics was performed using the Vitek 2 compact system. The minimum inhibitory concentrations (MICs) were detected using the AST cards of Vitek 2 compact system for oxacillin (OXA), cefoxitin (FOX), ciprofloxacin (CIP), moxifloxacin (MOX), vancomycin (VA), trimethoprim/sulfamethoxazole (SXT), gentamicin (CN), clindamycin (DA), erythromycin (E) and linezolid (LZD). The steps were completed following the manufacturer’s instructions, and the results were read after 10–20 h (BioMerieux, France). MIC results were obtained and CLSI guidelines were used to interpret the findings.

Broth Microdilution Test for Chlorhexidine

The CLSI and Manual of Clinical Microbiology recommend a broth microdilution procedure using 96-well microtiter plates with two-fold serial dilutions to determine the MIC of chlorhexidine. The MIC is defined as the lowest concentration of antimicrobial agent that prevents observable growth following a 20-h incubation period at 37°C in Mueller–Hinton broth.

The isolates were considered resistant to chlorhexidine when the MIC was ≥ 4 μg/mL and the susceptibility breakpoint for chlorhexidine applied in this study was derived from the MIC epidemiological cut-off, a standard approach employed when validated breakpoints are not available, allowing our results to be compared to those in published reports. An increase in MIC values to chlorhexidine does not mean “resistance,” because this agent can be used at high concentrations without causing toxicity. Thus the terms “reduced susceptibility” or “increased tolerance” are better used for pathogens exhibiting an elevated MIC to chlorhexidine.

When the MIC for chlorhexidine was less than 4 μg/mL, the isolates were deemed susceptible. Because chlorhexidine can be used in high quantities without causing toxicity, an increase in MIC values does not imply “resistance.” Thus, microorganisms with an increased MIC to chlorhexidine are better described as having "reduced susceptibility" or "enhanced tolerance".

Table 1. Primers used for the detection of mecA, qacA/B and qacC genes and expected product size

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence (5'-3')</th>
<th>Amplicon size (bp)</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>mecA forward</td>
<td>F: GTA GAA ATG ACT GAA CGT CCG ATA A</td>
<td>310</td>
<td>[1]</td>
</tr>
<tr>
<td>mecA reverse</td>
<td>R: CCA ATT CCA CAT TGT TTC GGT CTA A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>qacA/B forward</td>
<td>F: CTA TGG CAA TAG GAG ATA TGG TGT</td>
<td>321</td>
<td>[1]</td>
</tr>
<tr>
<td>qacA/B reverse</td>
<td>R: CCA CTA CAG ATT CTT CAG CTA CAT G</td>
<td></td>
<td></td>
</tr>
<tr>
<td>qacC forward</td>
<td>F: GGC TTT TCA AAA TTT ATA CCA TCC T</td>
<td>249</td>
<td>[1]</td>
</tr>
<tr>
<td>qacC reverse</td>
<td>R: ATG CGA TGT TCC GAA AAT GT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Detection of *mecA*, *qacA/B*, and *qacC* Genes using PCR

Following the manufacturer’s instructions, genomic DNA was extracted from pure colonies of the isolated *S. aureus* using a DNA Mini Purification Kit (Qiagen, USA). The *mecA*, *qacA/B*, and *qacC* genes (Table 1) were detected using a conventional PCR test in a volume of 20 µL with approximately 2 mg of extracted DNA, using 10 µM primers, ready-made PCR master mix, and solution nuclease-free water (Thermo Scientific, USA).  

Initial denaturation at 95°C for 5 min was followed by 35 cycles of denaturation at 95°C for 30 s, annealing (59°C for *mecA*, 58°C for *qacA/B*, and 56°C for *qacC*) for 30 s, and extension at 72°C for 30 s. This was followed by a 10-minute final extension at 72°C. The predicted amplicons for *mecA*, *qacA/B*, and *qacC* were 310, 321, and 249 bp in length, respectively.

**RESULTS**

A total of 100 *S. aureus* clinical isolates were collected from different clinical specimens representing 1.9% of the total specimens received (100/5172), 2.5% of all clinical isolates (100/3984), 9% of the total Gram positive isolates (100/1104). In the present, study *S. aureus* represented 11.1% of the total isolated staphylococci (100/900). This study was performed on only 84 and 16 isolates of MRSA & MSSA respectively that could be elicited with the total number of 100 *S. aureus* isolates.

The specimens collected from the outpatient clinic were representing 16% (16/100) while specimens collected from inpatients were 84% (84/100). Urine were the major specimens collected from inpatients were (39.2%) followed by blood (32.1%) and then pus (19.04%), while in outpatients it was mainly urine (93.7%). Most of the inpatients specimens were recovered from the intensive care unit representing 28.5% (24/84) of the total specimens followed by urology department in 22.6% (19/84).

MRSA isolates, 84/100 *S. aureus* (84%), were phenotypically identified using Kirby–Bauer disc diffusion method via cefoxitin disc and using the Vitek 2 system, which determined oxacillin and cefoxitin MICs. All the isolates were sensitive to vancomycin and linezolid. Conversely, all the MSSA isolates were susceptible to linezolid, vancomycin, and trimethoprim/sulfamethoxazole (Table 2).

<table>
<thead>
<tr>
<th>Antibiotic(s)</th>
<th>MRSA</th>
<th>MSSA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sensitive</td>
<td>Resistant</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>84 (100%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Linezolid</td>
<td>84 (100%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>59 (70.23%)</td>
<td>25 (29.7%)</td>
</tr>
<tr>
<td>Moxifloxacin</td>
<td>59 (70.23%)</td>
<td>25 (29.7%)</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>57 (67.8%)</td>
<td>27 (32.1%)</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>54 (64.2%)</td>
<td>30 (35.7%)</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>40 (47.6%)</td>
<td>44 (52.3%)</td>
</tr>
<tr>
<td>Trimethoprim/ Sulphamethoxazole</td>
<td>36 (42.8%)</td>
<td>48 (57.1%)</td>
</tr>
</tbody>
</table>

Data are expressed as number (%)

Table 2. Antibiotic susceptibility of MRSA and MSSA isolates by Vitek2 system
Broth Microdilution Test for Chlorhexidine

The minimum inhibitory concentration (MIC) of chlorhexidine was then determined. The final chlorhexidine concentrations ranged from 0.5–256 µg/mL, and the MIC results ranged from 0.5–128 µg/mL (Table 3). The MIC inhibiting 90% of isolates (MIC90) for chlorhexidine against MRSA were 16 µg/mL and in MSSA was 8 µg/mL. Out of 84 MRSA isolates, 61.9% (52/84) were sensitive to chlorhexidine, whereas 38.1% (32/84) isolates were resistant. On the other hand, 68.8% (11/16) MSSA isolates were sensitive to chlorhexidine and 31.2% (5/16) were resistant (Table 3). No statistically significant difference was found in the chlorhexidine results among the MRSA and MSSA isolates (P = 0.603).

Molecular Detection of meca, qacA, qacB, and qacC Genes using PCR

The presence of meca was detected using PCR (Figure 1). Out of 100 S. aureus strains, 84 (84%) were found to contain meca, verifying them as MRSA; 82.1% (69/84) were from inpatients, and 17.9% (15/84) outpatients. meca gene was absent in the remaining 16 (16%) strains (MSSA).

The presence of the quaternary ammonium resistance genes qacA/B and qacC was examined in 100 S. aureus strains. The qacA/B was the most common biocide resistance gene, being detected in 34% (34/100) of S. aureus isolates (Figure 2, 3), of which 94.1% (32/34) were from inpatients, 5.9% (2/34) outpatients, while qacC was the least prevalent, only found in 5% (5/100) of S. aureus isolates, of which 80% (4/5) were from inpatients, and 20% (1/5) outpatients (Figure 3).

Compared to MSSA, genes for resistance to quaternary ammonium compounds were found to be more prevalent in MRSA. The qacA/B genes were detected in 34.5% (29/84) of MRSA isolates and in 31.2% (5/16) of MSSA isolates, while qacC was found out in 5.95% (5/84) of MRSA isolates, and it was not detected in any MSSA isolate. None of the S. aureus isolates harbored either of these genes. However, no statistically significant difference was found regarding qacA/B and qacC abundance, among MRSA and MSSA isolates (P = 0.8 and 0.317, respectively).

The presence of antiseptic resistance genes in S. aureus isolates was compared with the MIC results for chlorhexidine. The qacA/B gene was found in 34 isolates, 32 (94.1%) of which were resistant to chlorhexidine. This gene, instead, was found in 2 (5.9%) chlorhexidine-susceptible isolates. The qacC gene was found in 5 isolates that were resistant to chlorhexidine, whereas this gene was not detected in any of the chlorhexidine-susceptible isolates. In MRSA and MSSA isolates, there was a statistically significant association between qacA/B, qacC, and chlorhexidine resistance (P = 0.001 and 0.006, respectively; Table 4).

Table 3. Chlorhexidine minimum inhibitory concentration values for MRSA and MSSA isolates

<table>
<thead>
<tr>
<th>Chlorhexidine</th>
<th>Number (% of isolates with related MIC,µg/ml)</th>
<th>MIC50 µg/ml</th>
<th>MIC90 µg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRSA</td>
<td>0.5 1 2 4 8 16 32 64 128</td>
<td>15 19 18 8 13 2 2 6 1</td>
<td>2 16</td>
</tr>
<tr>
<td>(no= 84)</td>
<td>17.8% (22%) (21.4%) (9.5%) (15.4%) (2.3%) (2.3%) (7.1%) (1.1%)</td>
<td>2 0 0 2 0 2 8</td>
<td></td>
</tr>
<tr>
<td>MSSA</td>
<td>2 3 6 1 2 0 0 2 0</td>
<td>12.5% (18.7%) (37.5%) (6.2%) (12.5%) (0%) (12.5%) (0%)</td>
<td></td>
</tr>
<tr>
<td>(no = 16)</td>
<td>12.5% (18.7%) (37.5%) (6.2%) (12.5%) (0%) (12.5%) (0%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DISCUSSION

Recently, evidence for the development of resistance to antiseptics has been increasing. The decreased sensitivity to chlorhexidine is caused by qacA and qacB, which are placed in plasmids and are highly closely linked. The qacA and qacB genes encode a proton-dependent efflux pump (QacA/QacB), a member of the major facilitator superfamily of transport proteins, in the form of 14α-helical transmembrane segments able to pump chlorhexidine out of bacteria.

Although chlorhexidine is not used in TBRI hospital, this study was performed to evaluate its future use to follow the CDC recommendations for hand hygiene and body
washing of patients with MRSA (CDC, 2017). Instead, a panel of antiseptics and disinfectants are used in TBRI hospital, including alcohol hand rub gel (2-propanol 45+1-propanol 30) for hands and QAC foam of didecyldimethylammonium chloride+biguanide. For surfaces, QAC: benzyl-C12-18-alkyldimethyl–ammoiumchlorides N-(3 aminopropyl)-n-dodecylpropane-1,3-diamine, chlorine: sodium dichloroisocyanurate tablets and sodium hypochlorite, and sodium hydroxide are used. Effervescent granules of sodium dichloroisocyanurate are used for blood and body fluid spills. For surfaces, skin, and air, hydrogen peroxide: 0.5–1% (surfaces and fabrics), 3% (skin, minor cuts), 6% (airborne isolation), 12% (transplantation). While reprocessing of endoscopes and preoperative skin preparation, activated glutaraldehyde solution and povidone–iodine 10% W/V, respectively, are used.

This study aimed to determine the occurrence of antiseptic resistance genes (qacA/B and qacC) in clinical isolates of MSSA and MRSA. We also studied the correlation between mecA gene existence and different antiseptic resistance genes (qacA/B and qacC) in MRSA isolates and determined the association between the occurrence of qacA/B and qacC genes and susceptibility to chlorhexidine to evaluate its future use in TBRI hospital.

A total of 100 S. aureus clinical isolates were obtained from different clinical samples, representing 1.9% of the total specimens received (100/5172). A higher rate of S. aureus was isolated from clinical specimens (30/300, 10%) in a study from Rwanda. Additionally, a higher rate was detected in a study from Ethiopia (14.3%). In our study, S. aureus was identified in 2.5% of all clinical isolates (100/3984). A previous study revealed that the proportion of S. aureus identified, in comparison with the total clinical isolates, was 19.96%. In the current study, S. aureus represented 10.9% of the total Gram positive isolates (100/3984). A higher prevalence of S. aureus was detected in Gram positive isolates in a previous study (48.8%). In the present study, S. aureus represented 11.1% of all staphylococci

<table>
<thead>
<tr>
<th>Antiseptic</th>
<th>Methicillin resistance gene</th>
<th>Quaternary ammonium resistance genes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>meca (+) (n = 84)</td>
<td>qacA/B (+) (n = 34)</td>
</tr>
<tr>
<td></td>
<td>meca (-) (n = 16)</td>
<td>qacA/B (-) (n = 66)</td>
</tr>
<tr>
<td></td>
<td>qacC (+) (n = 5)</td>
<td>qacC (-) (n = 95)</td>
</tr>
<tr>
<td>&lt;4 μg/ml</td>
<td>52 (61.9%)</td>
<td>2 (5.9%)</td>
</tr>
<tr>
<td>(Susceptible)</td>
<td>11 (68.8%)</td>
<td>61 (92.4%)</td>
</tr>
<tr>
<td>(n = 63)</td>
<td></td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Chlorhexidine</td>
<td>63 (66.3%)</td>
<td>63 (66.3%)</td>
</tr>
<tr>
<td>≥ 4 μg/ml</td>
<td>32 (38.1%)</td>
<td>32 (94.1%)</td>
</tr>
<tr>
<td>(Resistant)</td>
<td>5 (31.2%)</td>
<td>5 (100%)</td>
</tr>
<tr>
<td>Chi-square test</td>
<td>0.270</td>
<td>8.962</td>
</tr>
<tr>
<td>p-value</td>
<td>0.603</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Figure 1. Agarose gel electrophoresis of representative PCR products of S. aureus meca positive gene (310bp) M: molecular weight marker (ladder 50 bp), Lane 1: positive control, Lane 2-6: positive DNA samples meca PCR amplification product, Lane 7: negative control
species isolated (100/900). A previous study reported a S. aureus prevalence of 54.3% of all Staphylococcus strains isolated.\textsuperscript{17}

In the current study, it was found that (84/100) 84% of isolates were confirmed to be MRSA. Our result is comparable to a recent study by Elsherif et al. (2020), who reported a MRSA prevalence of 92.3% of all S. aureus isolates.\textsuperscript{18} According to many studies, the frequency of MRSA among hospitalized patients in Egypt ranges from 50 to 82 percent.\textsuperscript{19} However, lower rates were reported in two different studies conducted Abd El-Baky et al.\textsuperscript{20} and Ahmed et al.,\textsuperscript{21} who found that methicillin resistance represented 25.4% and 15% of S. aureus isolates, respectively.\textsuperscript{20,21} Additionally, Elshabrawy et al.,\textsuperscript{22} reported a prevalence of 40% in Mansoura University hospital.

Similar to our results, studies originating from the Kingdom of Saudi Arabia reported that MRSA accounted for 77.5 to 90% of all S. aureus isolates.\textsuperscript{23,24} In addition, studies from Nepal have reported MRSA prevalence rates ranging from 69.1 to 75.5%.\textsuperscript{25-27} Another study in Iran reported that methicillin resistance represented 85% of S. aureus isolates.\textsuperscript{28} However, in Europe, different lower prevalence rates of MRSA were recorded in various regions: Germany (1%), Belgium (2–43%), United Kingdom (5–23%), Spain (16%), Romania (34%), Italy (37%), France (38%), Greece (40%), and Portugal (49%).\textsuperscript{29} Furthermore, Diekema et al.,\textsuperscript{30} revealed lower prevalence in hospitals in the United States of America (USA), stating that MRSA accounts for 30–50% of all nosocomial S. aureus isolates. In USA, the incidence of hospital- and community-acquired MRSA infections decreased by 74% and 40%, respectively, from 2005 to 2016. The decline in MRSA infections could be attributed to a variety of infection control initiatives, including improvements in preventing device- and procedure-related infections, as well as efforts that aided in disrupting MRSA transmission in the hospitals.\textsuperscript{31}

MRSA infection prevalence was a noticeable difference in the prevalence of MRSA infection. The difference in MRSA prevalence rates could be probably attributed to differences in the studied populations and discrepancies in the infection control procedures applied, along with unreasonable antibiotic use. Some researchers used active surveillance cultures, whereas
others used a culture of clinical specimens. The high rates stated in this study could be due to the long duration of the study and injudicious use of antibiotics, as the percentage of systemic antibiotics that can potentially elicit methicillin-resistant strains, traded at drug stores without a prescription is high in our community, resulting in an elevated resistance to antimicrobial agents and allowing the transfer of resistance between hospitals and the community.

In our study, the MRSA isolates were more resistant towards the tested antibiotics than the MSSA isolates. However, no isolates showed decreased sensitivity to vancomycin and linezolid. Interestingly, 57.1% of MRSA strains were resistant to trimethoprim/sulfamethoxazole, whereas none of the MSSA strains were resistant to it. MRSA infections, including endocarditis, bone and joint infections, and meningitis, are routinely treated with antibiotics. This treatment strategy could be worrying sign and lead to a rise in resistance toward the antibiotics.

Some proportion of MRSA isolates (52.3% and 35.7%) exhibited elevated resistance to gentamicin and erythromycin, respectively. These two antibiotics are commonly and randomly used to treat a variety of illnesses, including generalized and pyogenic infections.27,28 More than 25% of MRSA isolates were resistant to gentamicin, trimethoprim/sulfamethoxazole, and erythromycin, consistent with Gurung et al.’s results; however, none of the MRSA isolates were resistant to vancomycin. Additionally, these antibiotics showed less than 50% resistance towards the isolated MSSA. This could be explained by the fact that the mecA gene in MRSA is found on the staphylococcal cassette chromosome mec, which also encodes genes for various antibiotics, including aminoglycosides.1,33

In the present study, 38.1% and 31.2% of MRSA and MSSA isolates had decreased sensitivity to chlorhexidine, respectively, in line with Askar et al.’s study which stated that 42% of MRSA had reduced susceptibility to chlorhexidine, whereas all MSSA isolates were susceptible. Ignak et al. reported that 50% of MRSA and 15% of MSSA had reduced susceptibility to chlorhexidine. Moreover, Dittmann et al. reported that 65% of MRSA and 5% of MSSA had decreased sensitivity to chlorhexidine.

In the current study, all S. aureus isolates were tested for the presence of the quaternary ammonium resistance genes qacA/B and qacC using PCR. qacA/B was more dominant, being found in 34% of S. aureus isolates (MRSA 34.5% and MSSA 31.2%), whereas qacC was less common, only detected in 5% of S. aureus isolates (MRSA 5.95% and MSSA 0%). This result is comparable to the Egyptian study by Askar et al., where qacA/B was found in 47.4% of MRSA isolates, whereas qacC was found in 28.9% of these isolates. Moreover, John et al.,34 and Htun et al.35 revealed that the prevalence of qacA/B gene was 35.08% and 46.6%, while that of qacC was 4.7% and 13.6%, respectively.34,35 Our results are in partial agreement with a study from Japan, which reported qacA/B genes to be more abundant in MRSA (32.6%) and MSSA (7.5%) isolates than qacC genes, which were found to be 3.3% in MRSA and 5.9% in MSSA.36 Meyer et al.37 discovered that qacA/B genes were more common in 42% of S. aureus (63% MRSA and 12% MSSA) than the qacC gene, which was found in 5.8% of S. aureus (6.4% MRSA and 5% MSSA). A Malaysian study detected qacA/B gene at a much higher rate (83.3%) than qacC (1.9%) among their MRSA isolates.38 According to Duran et al., the prevalence of qacA/B genes in MRSA and MSSA isolates was 43.8% and 3.3%, respectively, whereas the prevalence of the qacC gene was 5% and 2.5%, respectively.

In Japan, however, qacA/B genes were found in 14% of clinical MRSA isolates, while qacC genes in 28%.30 Longtin et al.41 found that in 334 MRSA isolates obtained from two Canadian intensive care units, qacC genes were more common (7%) than qacA/B genes (2%), and that no isolate carried both genes. Additionally, a study in Turkey reported that qacC (13.8%) was more
common than qacA/B (10.3%) among S. aureus isolates.\textsuperscript{10} ‘Qac’ symbolizes two major families, separating QacA and QacB (MFS superfamily members) from the qacC proteins that belong to the SMR superfamily, which could explain the differential predominance of qac genes (qacA/B and qacC).\textsuperscript{8} Except for some shared substrates and similar efflux functions, these two large protein families have little in common. The qacA and qacB genes were found on the chromosomes, and the plasmids pSK1 and pSK23. The genes are mostly prevalent in S. aureus and S. epidermidis, and show modest sequence variation. The qacC gene has been found on both conjugative and non-conjugative (rolling-circle) plasmids, and it has been identified and characterized in both S. aureus and coagulase-negative Staphylococcus species.\textsuperscript{3}

Despite the fact that MRSA had more qacA/B and qacC genes than MSSA, there was no statistically significant difference in the presence of these genes between MRSA and MSSA in this study. In contrast to our findings, Zhang et al.\textsuperscript{42} found that 50% of MRSA and 16% of MSSA were positive for the qacA/B gene, a statistically significant difference. Furthermore, several researchers found the frequency of qacA/B and qacC to be statistically significant among MRSA and MSSA.\textsuperscript{28,39} The lack of statistical significance in our study could be attributed to the relatively low number of MSSA isolates. The higher prevalence of qac genes in MRSA than in MSSA can be attributed to the fact that the resistance of MRSA isolates to disinfectants and antiseptic compounds is mediated mainly by plasmid-encoded qacA/B and qacC determinants. The occurrence of such determinants is occupied by MDR resistance patterns in MRSA isolates toward multiple targets, leading to cross-resistance between antibiotic and antiseptics in S. aureus isolates.\textsuperscript{43} In addition, the mecA gene on a mobile genomic island staphylococcal cassette chromosome is a carrier for virulence and other drug-resistant genes, as well as a vehicle for genetic exchange between staphylococci.\textsuperscript{28} More research is needed to understand gene transfer selection that leads to the dissemination of resistance genes for designing long-term strategies to cure microbial diseases.\textsuperscript{43}

In the present study, all S. aureus isolates exhibited with decreased sensitivity to chlorhexidine (MIC ≥ 4 µg/L) and harbored either qacA/B or qacC, in agreement with other studies reporting that all isolates carrying qacA/B or qacC had a chlorhexidine MIC ≥ 4 µg/mL.\textsuperscript{1,42} Despite all previous studies revealing a clear association between qacA/B and reduced susceptibility to chlorhexidine, the present study unravels that the distribution of the qacA/B genes is not confined to strains showing chlorhexidine resistance, whereas two isolates harboring qacA/B genes were susceptible to chlorhexidine, in agreement with other reports.\textsuperscript{3,35} This finding could be explained by the fact that gene expression is not guaranteed by the presence of the qacA/B genes. Transcription regulators, intensity of exposure, and past contact with cationic chemicals influence their expression.\textsuperscript{7} In a meta-analysis of the effectiveness of chlorhexidine gluconate bathing in minimizing infections among individuals in the intensive care unit (ICU), evidence indicated the benefit of daily chlorhexidine digluconate bathing in reducing MRSA infections. However, effectiveness may be influenced by the underlying baseline risk of these events in the ICU population. As a result, chlorhexidine digluconate bathing appears to be most beneficial when infection rates in the ICU population are high.\textsuperscript{44}

In this study, a statistically significant association between the existence of qacA/B and qacC and lower susceptibility to chlorhexidine was observed, consistent with research from Iran and Singapore, which found an association between the presence of qac genes and a chlorhexidine MIC ≥ 4 µg/mL.\textsuperscript{28,37} The existing chlorhexidine MICs for staphylococci harboring the qac gene may permit existence at in-use concentrations, even when relatively augmented resistance may allow continuance when leftover disinfectants are present.\textsuperscript{28} It must be noted that the overuse of chlorhexidine as a decontaminant may increase the number of MRSA isolates with qacA/B resistance genes.\textsuperscript{37}

In our study, inpatients had a higher rate of S. aureus infection (84%) than outpatients (16%), consistent with Rajbhandari et al.,\textsuperscript{45} and Gurung et al.,\textsuperscript{27} who found a greater prevalence in the inpatient setting (62.3% and 55.7%), compared to in outpatients (37.7% and 44.3%), respectively.\textsuperscript{45,27} Likewise, the distribution of mecA, qacA/B, and qacC genes in the patients was found to be 82.1%, 94.1, 80%, respectively, in
inpatients and 17.9%, 5.9%, and 20%, respectively, in outpatients.

Our result is in accordance with a study that found that mecA, qacA/B, and qacC were more dominant in inpatients than in outpatients.27 These findings suggest that nosocomial infections are more common in hospitals. Longer hospital stays, antibiotic treatment, underlying immunocompromised conditions, hospital environment, overuse of antiseptics and disinfectants, instrumentation, and use of other invasive devices could be the risk factors that predispose patients to MRSA acquisition.

CONCLUSION

This study revealed a high percentage of S. aureus isolates harboring the antiseptic resistance genes qacA/B or qacC, which were more common in MRSA than in MSSA isolates. The presence of qacA/B or qacC was linked to decreased susceptibility to chlorhexidine. However, the presence of qacA/B did not always imply a reduction in chlorhexidine susceptibility. The clinical use of chlorhexidine may continue to increase, implying the development of new clones with reduced susceptibility.

ACKNOWLEDGMENTS

The authors would like to thank Prof. Abdel Fattah Hassan Attia, Professor of Medical Microbiology and Immunology, Faculty of Medicine, Cairo University, Egypt for assigning this work, and supplied all necessary facilities for its success.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

FUNDING

This study was funded by Theodor Bilharz Research Institute under Internal Project (No. 110).

AUTHORS’ CONTRIBUTION

HB conceptualized the research. AR analyzed and interpreted the data. MS performed the microbiological identification and interpreted the results. AF collected samples, analyzed and interpreted the data. AS performed the molecular detection. NY performed the MIC and molecular detection. MS and AF wrote the manuscript. HB, AR, AF, RM, NY revised the manuscript. All authors read and approved the final manuscript for publication.

DATA AVAILABILITY

The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

ETHICS STATEMENT

The protocol of the study was approved by TBRI Institutional Review Board under Federal Wide Assurance (FWA00010609) and the work has been carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for Experiments in Humans and its later amendments (GCP guidelines) or comparable ethical standards.

REFERENCES


